Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bevacizumab

Bevacizumab Am J Cancer 2004; 3 (3): 195-196 GUEST COMMENTARIES 1175-6357/04/0003-0195/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. startling increase in all clinical measures of efficacy, including response rate, time to progression, and overall survival for the IFL A Viewpoint by Richard M. Goldberg plus bevacizumab arm of the trial. This was accomplished with a University of North Carolina Lineberger Comprehensive modicum of additive toxicity including modest, easily controlled Cancer Center, Chapel Hill, North Carolina, USA hypertension and rare bowel perforation. In the FU/LV plus bevacizumab arm of the study, enhanced activity, without signifi- Bevacizumab is a humanized monoclonal antibody specifically cantly increased toxicity, was observed based on comparison with directed against vascular endothelial growth factor, a potent stimu- historical controls, although the changes in outcomes were lower lator of angiogenesis. Initial evidence of activity with the murine in magnitude than those observed with IFL plus bevacizumab. component indicated specificity; the antibody caused tumor shrinkage, resulted in diminished blood vessel density, and It is not entirely clear if bevacizumab is best partnered with any worked only in vivo, all findings that support an antiangiogenic single chemotherapy regimen or if its efficacy is independent of mechanism of action. The http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Bevacizumab

Abstract

Am J Cancer 2004; 3 (3): 195-196 GUEST COMMENTARIES 1175-6357/04/0003-0195/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. startling increase in all clinical measures of efficacy, including response rate, time to progression, and overall survival for the IFL A Viewpoint by Richard M. Goldberg plus bevacizumab arm of the trial. This was accomplished with a University of North Carolina Lineberger Comprehensive modicum of additive toxicity including modest, easily controlled...
Loading next page...
 
/lp/springer-journals/bevacizumab-4VhfOQ7KsK
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403030-00006
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2004; 3 (3): 195-196 GUEST COMMENTARIES 1175-6357/04/0003-0195/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. startling increase in all clinical measures of efficacy, including response rate, time to progression, and overall survival for the IFL A Viewpoint by Richard M. Goldberg plus bevacizumab arm of the trial. This was accomplished with a University of North Carolina Lineberger Comprehensive modicum of additive toxicity including modest, easily controlled Cancer Center, Chapel Hill, North Carolina, USA hypertension and rare bowel perforation. In the FU/LV plus bevacizumab arm of the study, enhanced activity, without signifi- Bevacizumab is a humanized monoclonal antibody specifically cantly increased toxicity, was observed based on comparison with directed against vascular endothelial growth factor, a potent stimu- historical controls, although the changes in outcomes were lower lator of angiogenesis. Initial evidence of activity with the murine in magnitude than those observed with IFL plus bevacizumab. component indicated specificity; the antibody caused tumor shrinkage, resulted in diminished blood vessel density, and It is not entirely clear if bevacizumab is best partnered with any worked only in vivo, all findings that support an antiangiogenic single chemotherapy regimen or if its efficacy is independent of mechanism of action. The

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.